碘化钠转运体（NIS）在甲状腺癌患者管理中的应用
Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma.
作者信息
Chung June-Key, Kim Hyun Woo, Youn Haewon, Cheon Gi Jeong
机构信息
Department of Nuclear Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
出版信息
Nucl Med Mol Imaging. 2018 Oct;52(5):325-326. doi: 10.1007/s13139-018-0540-y. Epub 2018 Aug 27.
Abstract
Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.
摘要
尽管放射性碘已应用于包括甲状腺癌在内的甲状腺疾病治疗70多年，但直到1996年才确定碘摄取的基本分子机制。碘离子通过一种称为钠碘同向转运体（NIS）的膜糖蛋白被主动转运到甲状腺中。NIS介导放射性碘摄取进入甲状腺正常细胞和癌细胞。关于NIS表达的知识为甲状腺癌的经验性治疗提供了科学依据。基于对NIS基因的最新研究，本文介绍了其当前的临床应用及未来研究方向。
相似文献
1
Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma.碘化钠转运体（NIS）在甲状腺癌患者管理中的应用
Nucl Med Mol Imaging. 2018 Oct;52(5):325-326. doi: 10.1007/s13139-018-0540-y. Epub 2018 Aug 27.
2
Functional Radionuclide Imaging, In-Vitro Radioiodine Uptake Estimation and RT-PCR in the Evaluation of Sodium Iodide Symporter (NIS) Expression and Functionality in Breast Cancer: A Pilot Study.功能放射性核素成像、体外放射性碘摄取估计及逆转录聚合酶链反应在评估乳腺癌中碘化钠转运体（NIS）表达和功能的初步研究
Indian J Surg Oncol. 2013 Mar;4(1):80-91. doi: 10.1007/s13193-012-0205-8. Epub 2013 Jan 5.
3
Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.碘化钠同向转运体与甲状腺癌的放射性碘治疗
Nucl Med Mol Imaging. 2010 Apr;44(1):4-14. doi: 10.1007/s13139-009-0016-1. Epub 2010 Feb 26.
4
Sodium iodide symporter: its role in nuclear medicine.碘化钠同向转运体：其在核医学中的作用。
J Nucl Med. 2002 Sep;43(9):1188-200.
5
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.钠/碘同向转运体：甲状腺癌细胞代谢中的关键转运系统。
Eur J Endocrinol. 1999 Nov;141(5):443-57. doi: 10.1530/eje.0.1410443.
6
Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.将钠碘转运体重新引入间变性甲状腺癌。
Thyroid. 2017 Dec;27(12):1534-1543. doi: 10.1089/thy.2017.0290. Epub 2017 Nov 10.
7
Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.全反式维甲酸对人未分化甲状腺癌细胞系中钠/碘同向转运体表达、放射性碘摄取及基因表达谱的影响
Nucl Med Biol. 2006 Oct;33(7):875-82. doi: 10.1016/j.nucmedbio.2006.07.004.
8
[Sodium iodide symporter in physiology and diseases -- the current state of knowledge].[碘化钠同向转运体在生理与疾病中的研究现状]
Endokrynol Pol. 2007 Nov-Dec;58(6):512-21.
9
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and Mutation.甲状腺乳头状癌中放射性碘难治性、钠/碘同向转运体表达与突变之间的关联
Onco Targets Ther. 2021 Jun 29;14:3959-3969. doi: 10.2147/OTT.S308910. eCollection 2021.
10
The importance of sodium/iodide symporter (NIS) for thyroid cancer management.钠/碘同向转运体（NIS）在甲状腺癌治疗中的重要性。
Arq Bras Endocrinol Metabol. 2007 Jul;51(5):672-82. doi: 10.1590/s0004-27302007000500004.
引用本文的文献
1
Advancing in vitro assessment of iodide uptake inhibition: integrating a novel biotransformation pretreatment step.推进碘摄取抑制的体外评估：整合新型生物转化预处理步骤。
Arch Toxicol. 2025 May 12. doi: 10.1007/s00204-025-04034-y.
2
Thyroid Hormone Withdrawal versus Recombinant Human TSH as Preparation for I-131 Therapy in Patients with Metastatic Thyroid Cancer: A Systematic Review and Meta-Analysis.甲状腺激素撤减与重组人促甲状腺素用于转移性甲状腺癌患者碘-131治疗的准备：一项系统评价和荟萃分析
Cancers (Basel). 2023 Apr 27;15(9):2510. doi: 10.3390/cancers15092510.
3
Analysis of differences of ultrasound features in different courses of thyroid carcinoma.不同病程甲状腺癌超声特征差异分析
Am J Transl Res. 2021 Apr 15;13(4):3582-3590. eCollection 2021.
本文引用的文献
1
Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene.密码子优化的人钠碘同向转运体（opt-hNIS）作为一种灵敏的报告基因和高效的治疗性基因。
Theranostics. 2015 Jan 1;5(1):86-96. doi: 10.7150/thno.10062. eCollection 2015.
2
Lesionalized therapy beyond personalized therapy in cancer management.癌症管理中超越个性化治疗的病灶靶向治疗。
J Korean Med Sci. 2014 Oct;29(10):1331-2. doi: 10.3346/jkms.2014.29.10.1331.
3
Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.放射性碘治疗分化型甲状腺癌：肿瘤学中的首个靶向治疗。
Endocrinol Metab (Seoul). 2014 Sep;29(3):233-9. doi: 10.3803/EnM.2014.29.3.233.
4
Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma.葡萄糖转运蛋白-1基因和甲状腺特异性基因在人甲状腺乳头状癌中的表达模式
Nucl Med Mol Imaging. 2014 Jun;48(2):91-7. doi: 10.1007/s13139-013-0249-x. Epub 2014 Jan 25.
5
Relationship between expression of the sodium/iodide symporter and (131)I uptake in recurrent lesions of differentiated thyroid carcinoma.钠/碘同向转运体表达与分化型甲状腺癌复发病灶中碘-131摄取的关系
Eur J Nucl Med. 2001 May;28(5):639-45. doi: 10.1007/s002590100509.
6
Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.（124）I-PET/CT 和（18）F-FDG-PET/CT 对分化型甲状腺癌患者局部复发的定位效果。
J Korean Med Sci. 2012 Sep;27(9):1019-26. doi: 10.3346/jkms.2012.27.9.1019. Epub 2012 Aug 22.
7
Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.甲状腺微小乳头状癌隐匿性颈转移淋巴结中钠碘同向转运体和促甲状腺激素受体的表达。
Ann Surg Oncol. 2012 Mar;19(3):990-5. doi: 10.1245/s10434-011-2047-y. Epub 2011 Aug 31.
8
The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer.分化型甲状腺癌患者 I-131 治疗的获益与风险。
Thyroid. 2009 Dec;19(12):1381-91. doi: 10.1089/thy.2009.1611.
9
Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model.野生型 p53 增强了使用钠碘转运体的放射性核素基因治疗在小鼠间变性甲状腺癌模型中的细胞毒性作用。
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):235-41. doi: 10.1007/s00259-009-1251-5. Epub 2009 Sep 1.
10
Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.维甲酸治疗对甲状腺癌再分化及放射性碘摄取恢复的有效性。
J Endocrinol Invest. 2009 Mar;32(3):228-33. doi: 10.1007/BF03346457.
Zotero 插件